Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ASCLF Stock Alerts

Ascletis Pharma (ASCLF) News Today

Ascletis Pharma logo
$1.30 0.00 (0.00%)
As of 08/21/2026
Compare

Ascletis Pharma Latest News

Ascletis Pharma (ASCLF) to Release Earnings on Monday
August 24 at 1:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30979085
Ascletis Pharma Inc.
August 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/ASCLF/financials
Ascletis receives FDA clearance to begin Phase III ASC30 programme
August 4, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/ascletis-receives-fda-clearance-begin-094651014.html
Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend
August 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-schedules-board-meeting-to-review-2026-interim-results-and-dividend?utm_source=marketbeat.com&utm_medium=referral
Ascletis Pharma Inc Ordinary Shares ASCLF
July 30, 2026  |  morningstar.comM
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
June 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-launches-hk300-million-share-buyback-under-mandate?utm_source=marketbeat.com&utm_medium=referral
Ascletis receives FDA clearance for Phase I trial of obesity treatment
June 24, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ascletis-receives-fda-clearance-for-phase-i-trial-of-obesity-treatment/ar-AA26sBqI
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
June 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-us-fda-ind-clearance-for-phase-i-study-of-once-monthly-subcutaneously-administered-glp-1rgipr-dual-peptide-agonist-asc35-for-the-treatment-of-obesity-302807534.html
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
June 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
May 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-33rd-european-congress-on-obesity-eco-2026-302762737.html
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
April 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-to-unveil-obesity-and-metabolic-drug-data-at-ada-2026?utm_source=marketbeat.com&utm_medium=referral
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
April 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions-302757192.html
Ascletis completes subject enrolment in Phase II ASC3 trial
April 27, 2026  |  yahoo.comhttps://www.yahoo.com/news/articles/ascletis-completes-subject-enrolment-phase-103202396.html
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
April 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-completes-enrollment-in-us-phase-ii-study-of-asc30-an-oral-small-molecule-glp-1r-agonist-for-the-treatment-of-diabetes-302753633.html
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
April 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-fixed-dose-combination-of-asc30-once-daily-oral-small-molecule-glp-1r-agonist-and-asc39-once-daily-oral-small-molecule-amylin-selective-amylin-receptor-agonist-for-clinical-development-302735615.html
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
March 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-ii-24-week-study-for-its-ultra-long-acting-subcutaneous-depot-formulations-of-small-molecule-glp-1r-agonist-asc30-for-obesity-302709245.html
Ascletis Pharma’s ASC36 Obesity Move Meets Strong Share Price Momentum
February 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/ascletis-pharma-asc36-obesity-move-140952583.html
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
February 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683756.html
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
February 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-raises-hk835-million-to-fund-global-phase-iii-obesity-drug-trials?utm_source=marketbeat.com&utm_medium=referral
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
February 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-to-raise-hk835-million-via-share-placement-to-fund-obesity-drug-trials?utm_source=marketbeat.com&utm_medium=referral
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in ...
February 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/sagimet-announces-positive-52-week-120000543.html
How Denifanstat’s Phase III Acne Results And NDA Progress At Ascletis Pharma (SEHK:1672) Has Changed Its Investment Story
February 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/denifanstat-phase-iii-acne-results-221041896.html
Ascletis reports positive results in Phase III denifanstat trial for acne
January 30, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ascletis-reports-positive-results-in-phase-iii-denifanstat-trial-for-acne/ar-AA1VllDe
Ascletis Acne Drug Shows Positive Phase Three Results
January 30, 2026  |  msn.comhttps://www.msn.com/en-sg/news/other/ascletis-acne-drug-shows-positive-phase-three-results/ar-AA1Vj9Lv
Ascletis initiates participant dosing in Phase II trial of ASC30 for diabetes
January 27, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ascletis-initiates-participant-dosing-in-phase-ii-trial-of-asc30-for-diabetes/ar-AA1V6qY5
Ascletis Begins Phase Two Diabetes Drug Trial
January 26, 2026  |  msn.comhttps://www.msn.com/en-sg/money/general/ascletis-begins-phase-two-diabetes-drug-trial/ar-AA1UYfSF
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
January 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-first-participants-dosed-in-a-13-week-us-phase-ii-study-with-asc30-an-oral-small-molecule-glp-1r-agonist-for-the-treatment-of-diabetes-302669405.html
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
January 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-selects-a-next-generation-once-monthly-subcutaneously-administered-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302665194.html
Ascletis receives FDA approval for diabetes mellitus clinical trial of ASC30
January 5, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ascletis-receives-fda-approval-for-diabetes-mellitus-clinical-trial-of-asc30/ar-AA1TCsBD
Ascletis wins FDA green light for phase II US diabetes trial of oral GLP-1 drug ASC30
January 4, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ascletis-wins-fda-green-light-for-phase-ii-us-diabetes-trial-of-oral-glp-1-drug-asc30/ar-AA1TzNag
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
January 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-us-fda-ind-clearance-for-13-week-phase-ii-study-of-its-oral-small-molecule-glp-1-asc30-in-participants-with-diabetes-302652107.html
Ascletis Pharma (SEHK:1672): Reassessing Valuation After a Sharp One-Day Pullback and Powerful 12-Month Rally
December 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ascletis-pharma-sehk-1672-reassessing-200828462.html
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
December 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-upsizes-share-repurchase-to-hk500-million-amid-drug-development-success?utm_source=marketbeat.com&utm_medium=referral
Ascletis Pharma Reports Positive Phase I Results for ASC50
December 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-reports-positive-phase-i-results-for-asc50?utm_source=marketbeat.com&utm_medium=referral
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
December 15, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-i-study-of-asc50-a-potential-best-in-class-oral-small-molecule-il-17-inhibitor-302641987.html
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
December 10, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharmas-acne-treatment-drug-application-accepted-by-china-nmpa?utm_source=marketbeat.com&utm_medium=referral
Shares of Chinese Drugmaker Ascletis Rise on Weight-Loss Drug Results
December 9, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/shares-of-chinese-drugmaker-ascletis-rise-on-weight-loss-drug-results-a0d6f402
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in ...
December 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ascletis-oral-small-molecule-glp-094000364.html
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
December 8, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharmas-asc30-shows-promising-results-in-obesity-treatment-study?utm_source=marketbeat.com&utm_medium=referral
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
December 8, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-oral-small-molecule-glp-1--asc30--demonstrated-placebo-adjusted-weight-loss-of-7-7-with-better-gastrointestinal-tolerability-in-its-13-week-us-phase-ii-study-in-participants-with-obesity-or-overweight-302635182.html
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
November 30, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-selects-its-first-oral-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302628537.html
Ascletis Pharma Advances ASC37 for Obesity Treatment
November 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-advances-asc37-for-obesity-treatment?utm_source=marketbeat.com&utm_medium=referral
Why Ascletis Pharma (SEHK:1672) Is Up 45.4% After Unveiling New Obesity Drug Data and US IND Plans
November 14, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/why-ascletis-pharma-sehk-1672-031540770.html
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical ...
November 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ascletis-announces-co-formulation-asc36-233000462.html
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
November 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-advances-obesity-treatment-with-new-co-formulation?utm_source=marketbeat.com&utm_medium=referral
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
November 12, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-announces-co-formulation-of-asc36-once-monthly-next-generation-amylin-receptor-agonist-and-asc35-once-monthly-next-generation-glp-1rgipr-dual-agonist-for-clinical-development-302613458.html
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
November 4, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascletis-pharma-unveils-promising-obesity-treatment-results-at-obesityweek-2025?utm_source=marketbeat.com&utm_medium=referral
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
November 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-presents-full-analysis-of-phase-ib-study-of-asc30-oral-tablet-phase-ib-study-of-asc30-injection-and-preclinical-study-of-combination-of-asc31-and-asc47-at-obesityweek-2025-302603810.html
Ascletis bets on once monthly ASC36 to fight obesity
October 30, 2025  |  msn.comhttps://www.msn.com/en-sg/health/weightloss/ascletis-bets-on-once-monthly-asc36-to-fight-obesity/ar-AA1PuhvY
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
October 29, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ascletis-selects-a-best-in-class-once-monthly-subcutaneously-administered-amylin-receptor-agonist-asc36-for-clinical-development-302598384.html

Ascletis Pharma Media Mentions By Week

Ascletis Pharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ASCLF
News Sentiment
▼
0.00

0.66
▲
Average
Healthcare
News Sentiment

Ascletis Pharma News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ASCLF Articles
This Week
▼
1

1
▲
ASCLF Articles
Average Week

Ascletis Pharma Trends on MarketBeat

This week vs. last week
Page Views
63
-13%
Get Ascletis Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Ascletis Pharma dated 8/15/2026.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel